Payables and Accruals [Abstract] Schedule of Accounts Payable and Accrued Expenses Schedule of Accounts Payable and Accrued Liabilities [Table Text Block] Investments, Debt and Equity Securities [Abstract] Fair value, due within one year Available-for-sale Securities, Debt Maturities, Next Twelve Months, Fair Value Fair value, due after one year through five years Available-for-sale Securities, Debt Maturities, Year Two Through Five, Fair Value Fair value Available-for-sale Securities, Debt Securities Net carrying amount, due within one year Available For Sale Securities Debt Maturities Within One Year Carrying Value Available For Sale Securities Debt Maturities Within One Year Carrying Value Net carrying amount, due after one year through five years Available For Sale Securities Debt Maturities After One Year Through Five Years Carrying Value Available For Sale Securities Debt Maturities After One Year Through Five Years Carrying Value. Net carrying amount Available For Sale Securities Debt Maturities Carrying Value Available For Sale Securities Debt Maturities Carrying Value Disclosure of Compensation Related Costs, Share-based Payments [Abstract] Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table] Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table] Award Type [Axis] Award Type [Axis] Equity Award [Domain] Equity Award [Domain] Employee Stock Option Employee Stock Option [Member] Range [Axis] Range [Axis] Range [Domain] Range [Domain] Minimum Minimum [Member] Maximum Maximum [Member] Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Expected dividend yield Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate Expected option term (years) Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term Expected stock price volatility Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate Risk-free interest rate Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate Marketable Securities Marketable Securities [Table Text Block] Maturities of Marketable Securities Investments Classified by Contractual Maturity Date [Table Text Block] Accounting Policies [Abstract] Summary of Significant Accounting Policies Significant Accounting Policies [Text Block] Organization, Consolidation and Presentation of Financial Statements [Abstract] Business Overview Business Description and Basis of Presentation [Text Block] Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table] Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table] Income Statement Location [Axis] Income Statement Location [Axis] Income Statement Location [Domain] Income Statement Location [Domain] Research and development Research and Development Expense [Member] General and administrative General and Administrative Expense [Member] Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items] Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items] Stock compensation expense Allocated Share-based Compensation Expense Marketable Securities Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block] Quarterly Financial Information Disclosure [Abstract] Summarized Unaudited Quarterly Financial Data Quarterly Financial Information [Table Text Block] Debt Disclosure [Abstract] Allocation of fair value to liability Allocation of Fair Value to Liability [Table Text Block] Allocation of Fair Value to Liability [Table Text Block] Deferred revenue, by arrangement Deferred Revenue, by Arrangement, Disclosure [Table Text Block] Segment Reporting [Abstract] Geographic Segments Segment Reporting Disclosure [Text Block] Deferred Revenue Arrangement, by Type [Table] Deferred Revenue Arrangement, by Type [Table] Counterparty Name [Axis] Counterparty Name [Axis] Counterparty Name [Domain] Counterparty Name [Domain] Rpi Finance Trust Rpi Finance Trust [Member] This member stands for RPI Finance Trust, a Delaware statutory trust. Sale of Stock [Axis] Sale of Stock [Axis] Sale of Stock [Domain] Sale of Stock [Domain] Private placement Private Placement [Member] Deferred Revenue Arrangement Type [Axis] Deferred Revenue Arrangement Type [Axis] Deferred Revenue [Domain] Deferred Revenue [Domain] Royalty Arrangement [Member] Royalty Arrangement [Member] Deferred Revenue Arrangement [Line Items] Deferred Revenue Arrangement [Line Items] Movement in Deferred Revenue [Roll Forward] Movement in Deferred Revenue [Roll Forward] Fair value, liability related to sale of future royalties, beginning balance Fair Value For Liability Related to Sale of Future Royalties Fair Value For Liability Related to Sale of Future Royalties Non-cash interest expenses Non Cash Interest Expense Related To Sale Of Future Royalties Non Cash Interest Expense Related To Sale Of Future Royalties Fair value, liability related to sale of future royalties, ending balance Related Party Transactions [Abstract] Schedule of Related Party Transactions, by Related Party [Table] Schedule of Related Party Transactions, by Related Party [Table] Performance Shares Performance Shares [Member] Title of Individual [Axis] Title of Individual [Axis] Relationship to Entity [Domain] Relationship to Entity [Domain] Chief Technology Officer [Member] Chief Technology Officer [Member] Represents information pertaining to chief technology officer. Related Party [Axis] Related Party [Axis] Related Party [Domain] Related Party [Domain] M Rosenberg Bio Pharma Consulting Llc [Member] M Rosenberg Bio Pharma Consulting Llc [Member] Represents information pertaining to consulting agreement. Related Party Transaction [Line Items] Related Party Transaction [Line Items] Professional and contract services expense Professional and Contract Services Expense Granted (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross Stock issued during period, net of forfeitures (in shares) Stock Issued During Period, Shares, Share-based Compensation, Net of Forfeitures Principles of consolidation and presentation Consolidation, Policy [Policy Text Block] Use of estimates Use of Estimates, Policy [Policy Text Block] Debt financing Debt, Policy [Policy Text Block] Foreign currencies Foreign Currency Transactions and Translations Policy [Policy Text Block] Fair value of financial instruments Fair Value of Financial Instruments, Policy [Policy Text Block] Marketable securities Marketable Securities, Policy [Policy Text Block] Concentration of credit risk Concentration Risk, Credit Risk, Policy [Policy Text Block] Revenue recognition Revenue Recognition, Policy [Policy Text Block] Research and development costs Research and Development Expense, Policy [Policy Text Block] Common Stock Warrants Common Stock Warrants Policy [Policy Text Block] Disclosure of accounting policy for common stock warrant liability. Fair value measurements Fair Value Measurement, Policy [Policy Text Block] Income taxes Income Tax, Policy [Policy Text Block] Net loss per share allocable to common stockholders Earnings Per Share, Policy [Policy Text Block] Net comprehensive loss Comprehensive Income, Policy [Policy Text Block] Stock-based compensation Share-based Compensation, Option and Incentive Plans Policy [Policy Text Block] Recently issued accounting pronouncements New Accounting Pronouncements, Policy [Policy Text Block] Schedule of Available-for-sale Securities [Table] Schedule of Available-for-sale Securities [Table] Major Types of Debt and Equity Securities [Axis] Major Types of Debt and Equity Securities [Axis] Major Types of Debt and Equity Securities [Domain] Major Types of Debt and Equity Securities [Domain] U.S. Treasury Bonds US Treasury Securities [Member] Certificate of Deposits Certificates of Deposit [Member] U.S. Government Sponsored Agencies US Government-sponsored Enterprises Debt Securities [Member] Corporate Debt Securities Corporate Debt Securities [Member] Commercial Paper Commercial Paper [Member] Schedule of Available-for-sale Securities [Line Items] Schedule of Available-for-sale Securities [Line Items] Amortized cost Available-for-sale Debt Securities, Amortized Cost Basis Gross unrealized gain Available-for-sale Debt Securities, Accumulated Gross Unrealized Gain, before Tax Gross unrealized (loss) Available-for-sale Debt Securities, Accumulated Gross Unrealized Loss, before Tax Fair value Statement of Financial Position [Abstract] Statement [Table] Statement [Table] Class of Stock [Axis] Class of Stock [Axis] Class of Stock [Domain] Class of Stock [Domain] Convertible preferred stock Convertible Preferred Stock [Member] Statement [Line Items] Statement [Line Items] Accounts receivable, allowance for doubtful accounts Allowance for Doubtful Accounts Receivable, Current Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment Preferred stock, par value (in USD per share) Preferred Stock, Par or Stated Value Per Share Preferred stock, shares authorized (in shares) Preferred Stock, Shares Authorized Preferred stock, shares issued (in shares) Preferred Stock, Shares Issued Preferred stock, shares outstanding (in shares) Preferred Stock, Shares Outstanding Common stock, par value (in USD per share) Common Stock, Par or Stated Value Per Share Common stock, shares authorized (in shares) Common Stock, Shares Authorized Common stock, shares issued (in shares) Common Stock, Shares, Issued Common stock, shares outstanding (in shares) Common Stock, Shares, Outstanding Treasury stock, shares (in shares) Treasury Stock, Shares Equity [Abstract] Components of Accumulated Other Comprehensive (Loss) Income Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block] Schedule of Segment Reporting Information, by Segment [Table] Schedule of Segment Reporting Information, by Segment [Table] Geographical [Axis] Geographical [Axis] Geographical [Domain] Geographical [Domain] United States UNITED STATES Europe Europe [Member] Segment Reporting Information [Line Items] Segment Reporting Information [Line Items] Total assets Assets Property, plant and equipment, net Property, Plant and Equipment, Net Revenues Revenue, Net Loss before income tax Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest Income Tax Disclosure [Abstract] Income Taxes Income Tax Disclosure [Text Block] Accounts Payable and Accrued Expenses Accounts Payable and Accrued Liabilities Disclosure [Text Block] Fair Value Disclosures [Abstract] Fair Value Measurements, Recurring and Nonrecurring [Table] Fair Value Measurements, Recurring and Nonrecurring [Table] Fair Value, Hierarchy [Axis] Fair Value, Hierarchy [Axis] Fair Value Hierarchy [Domain] Fair Value Hierarchy [Domain] Level 1 Fair Value, Inputs, Level 1 [Member] Level 2 Fair Value, Inputs, Level 2 [Member] Level 3 Fair Value, Inputs, Level 3 [Member] Investment Type [Axis] Investment Type [Axis] Investments [Domain] Investments [Domain] Money Market Funds Money Market Funds [Member] Debt Security Category [Axis] Debt Security Category [Axis] Other than Temporary Impairment, Credit Losses Recognized in Earnings, Categories of Investments [Domain] Other than Temporary Impairment, Credit Losses Recognized in Earnings, Categories of Investments [Domain] Marketable Securities Marketable Securities [Member] Marketable Securities [Member] Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Financial assets Assets, Fair Value Disclosure Commitments and Contingencies Disclosure [Abstract] Schedule of Guarantor Obligations [Table] Schedule of Guarantor Obligations [Table] Finite-Lived Intangible Assets by Major Class [Axis] Finite-Lived Intangible Assets by Major Class [Axis] Finite-Lived Intangible Assets, Major Class Name [Domain] Employment Agreement [Member] Employment Contracts [Member] Restricted Units Vesting Based on Certain Market Conditions [Member] Restricted Units With Vesting Market Conditions [Member] Restricted Units with Vesting Market Conditions [Member] Goldenberg Agreement [Member] Goldenberg Agreement [Member] Goldenberg Agreement [Member] Sullivan Agreement [Member] Sullivan Agreement [Member] Sullivan Agreement [Member] Goldenberg and Sullivan Goldenberg And Sullivan [Member] Represents Goldenberg and Sullivan member. Guarantor Obligations [Line Items] Guarantor Obligations [Line Items] Total foregoing cash payments Loss Contingency, Foregoing Cash Payments Accumulated Amount of foregone cash payment accumulated. Litigation settlement payment in dispute Litigation Settlement Payment in Dispute Amount of litigation settlement payment in dispute. Restricted stock units granted Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period Litigation settlement, expense Litigation Settlement, Expense Operating leases, rent expense, net Operating Leases, Rent Expense, Net Purchase obligation, due in second year Purchase Obligation, Due in Second Year Trade accounts payable Accounts Payable, Trade, Current Clinical trial accruals Clinical Trials Clinical Trials Executive severance liabilities Supplemental Unemployment Benefits, Severance Benefits Reimbursement for proxy expenses Proxy Expenses Reimbursement, Current Carrying value as of the balance sheet date of obligations incurred towards proxy expense reimbursement. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). Contract manufacture organization expenses Contract Manufacture Organization Expenses Payable Current Carrying value as of the balance sheet date of obligations incurred towards contract manufacture organization expenses. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). Proxy defense-related expenses Proxy Defense Related Expenses Payable, Current Carrying value as of the balance sheet date of obligations incurred towards proxy defense expenses. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). Miscellaneous other current liabilities Other Current Liabilities Other Current Liabilities Accounts payable and accrued expenses Accounts Payable and Accrued Liabilities, Current Income Statement [Abstract] Revenues: Revenue, Net [Abstract] Product sales Sales Revenue, Goods, Net License fee and other revenues Licenses Revenue Research and development Revenue from Grants Total revenues Costs and Expenses: Operating Costs and Expenses [Abstract] Costs of goods sold Cost of Goods Sold Research and development Research and Development Expense Sales and marketing Selling and Marketing Expense General and administrative General and Administrative Expense Total costs and expenses Costs and Expenses Operating loss Operating Income (Loss) Changes in fair market value of warrant liabilities Fair Value Adjustment of Warrants Warrant related expenses Adjustment of Warrants Granted for Services Interest expense Interest Expense Interest and other income Interest and Other Income Other financing expenses Debt Issuance Costs Incurred During Noncash or Partial Noncash Transaction Insurance reimbursement Reimbursement Revenue Foreign currency transaction gain (loss), net Foreign Currency Transaction Gain (Loss), before Tax Income tax (expense) benefit Income Tax Expense (Benefit) Net loss Net Income (Loss), Including Portion Attributable to Noncontrolling Interest Net loss attributable to noncontrolling interest Net Income (Loss) Attributable to Noncontrolling Interest Net loss attributable to Immunomedics, Inc. stockholders Net Income (Loss) Attributable to Parent Loss per common share attributable to Immunomedics, Inc. stockholders (basic and diluted) (in USD per share) Earnings Per Share, Basic and Diluted Weighted average shares used to calculate loss per common share (basic and diluted) (in shares) Weighted Average Number of Shares Outstanding, Basic and Diluted Other comprehensive (loss) income, net of tax: Other Comprehensive Income (Loss), Net of Tax [Abstract] Foreign currency translation adjustments Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax Unrealized gain (loss) on securities available for sale Other Comprehensive Income (Loss), Unrealized Holding Gain (Loss) on Securities Arising During Period, Net of Tax Other comprehensive income (loss), net of tax: Other Comprehensive Income (Loss), Net of Tax Comprehensive loss Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest Comprehensive loss attributable to noncontrolling interest Comprehensive Income (Loss), Net of Tax, Attributable to Noncontrolling Interest Comprehensive loss attributable to Immunomedics, Inc. stockholders Comprehensive Income (Loss), Net of Tax, Attributable to Parent Document and Entity Information Document And Entity Information [Abstract] Entity Registrant Name Entity Registrant Name Entity Central Index Key Entity Central Index Key Current Fiscal Year End Date Current Fiscal Year End Date Entity Filer Category Entity Filer Category Document Type Document Type Document Period End Date Document Period End Date Document Fiscal Year Focus Document Fiscal Year Focus Trading Symbol Trading Symbol Document Fiscal Period Focus Document Fiscal Period Focus Amendment Flag Amendment Flag Entity Common Stock, Shares Outstanding Entity Common Stock, Shares Outstanding Entity Well-known Seasoned Issuer Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Voluntary Filers Entity Current Reporting Status Entity Current Reporting Status Entity Public Float Entity Public Float Current Current Federal Tax Expense (Benefit) Deferred Deferred Federal Income Tax Expense (Benefit) Total Federal Federal Income Tax Expense (Benefit), Continuing Operations Current Current State and Local Tax Expense (Benefit) Deferred Deferred State and Local Income Tax Expense (Benefit) Total State State and Local Income Tax Expense (Benefit), Continuing Operations Current Current Foreign Tax Expense (Benefit) Deferred Deferred Foreign Income Tax Expense (Benefit) Total Foreign Foreign Income Tax Expense (Benefit), Continuing Operations Total Expense (Benefit) Statement of Cash Flows [Abstract] Cash flows from operating activities: Net Cash Provided by (Used in) Operating Activities [Abstract] Net loss Adjustments to reconcile net loss to net cash used in operating activities: Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract] Changes in fair value of warrant liabilities Warrant related expense Depreciation and amortization Depreciation, Depletion and Amortization, Nonproduction Interest on non-recourse debt Interest Expense, Debt Loss on induced exchanges of debt Loss On Induced Exchanges Of Debt Loss On Induced Exchanges Of Debt Deferred revenue, net of amortization Amortization Of Deferred Revenue1 Amortization of deferred revenue1. Amortization of bond premiums Accretion (Amortization) of Discounts and Premiums, Investments Amortization of debt issuance costs Amortization of Debt Issuance Costs Amortization of deferred rent Increase (Decrease) in Deferred Charges Loss (gain) on sale of marketable securities Gain (Loss) on Sale of Securities, Net (Decrease) increase in allowance for doubtful accounts Provision for Doubtful Accounts Non-cash expense related to stock compensation Share-based Compensation Non-cash decrease in value of life insurance policy Increase (Decrease) in Insurance Assets Non-cash financing expenses Other Noncash Expense Changes in operating assets and liabilities Increase (Decrease) in Operating Capital [Abstract] Accounts receivable - net of reserve Increase (Decrease) in Accounts Receivable Inventories - net of reserve Increase (Decrease) in Restricted Cash Other receivables Increase (Decrease) in Inventories Prepaid expenses Increase (Decrease) in Other Receivables Other current assets Increase (Decrease) in Prepaid Expense Accounts payable and accrued expenses Increase (Decrease) in Other Current Assets Purchases from sales/maturities of marketable securities Net Cash Provided by (Used in) Operating Activities Cash flows from investing activities: Net Cash Provided by (Used in) Investing Activities [Abstract] Purchases of marketable securities Payments to Acquire Available-for-sale Securities, Debt Purchases from sales/maturities of marketable securities Proceeds from Sale and Maturity of Available-for-sale Securities Purchases of property and equipment Payments to Acquire Property, Plant, and Equipment Net cash provided by (used in) investing activities Net Cash Provided by (Used in) Investing Activities Cash flows from financing activities: Net Cash Provided by (Used in) Financing Activities [Abstract] Exercise of stock options Proceeds from Stock Options Exercised Exercise of warrants Proceeds from Warrant Exercises Sale of preferred stock, net of related expenses Proceeds from Issuance of Preferred Stock and Preference Stock Proceeds from public offering of common stock Proceeds from Issuance Initial Public Offering Proceeds from private offering of common stock Proceeds from Issuance of Common Stock Proceeds from the issuance of non-recourse debt Proceeds from Issuance of Non-Recourse Debt The cash inflows from amounts received from a non-recourse debt. Debt conversion fees Payment of Debt Conversion Fees The cash outflow associated with debt conversion fees. Tax withholding payments for stock compensation Payments Related to Tax Withholding for Share-based Compensation Net cash provided by financing activities Net Cash Provided by (Used in) Financing Activities Effect of changes in exchange rates on cash and cash equivalents Effect of Exchange Rate on Cash and Cash Equivalents Net increase (decrease) in cash and cash equivalents Cash and Cash Equivalents, Period Increase (Decrease) Cash and cash equivalents, beginning balance Cash and Cash Equivalents, at Carrying Value Cash and cash equivalents, ending balance Supplemental disclosure of cash flow information: Supplemental Cash Flow Information [Abstract] Accrued capital expenditures Interest Paid, Net Income taxes paid Income Taxes Paid, Net Schedule for non-cash investing and financing activities: Noncash Investing and Financing Items [Abstract] Issuance of Common Shares for Debt Conversion Debt Conversion, Original Debt, Amount Accrued capital expenditures Capital Expenditures Incurred but Not yet Paid Liability Class [Axis] Liability Class [Axis] Fair Value by Liability Class [Domain] Fair Value by Liability Class [Domain] Warrant Warrant [Member] Class of Warrant or Right [Axis] Class of Warrant or Right [Axis] Class of Warrant or Right [Domain] Class of Warrant or Right [Domain] October 11, 2016 public offering Warrants issued in October 2016 [Member] Warrants issued in October 2016 February 10, 2017 stock purchase agreement Warrants issued on 10 February 2017 [Member] Warrants issued on 10 February 2017 Class of Warrant or Right [Line Items] Class of Warrant or Right [Line Items] Fair value assumptions for warrants Fair Value Assumptions and Methodology for Assets and Liabilities [Abstract] Risk-free interest rate Fair Value Assumptions, Risk Free Interest Rate Expected remaining term Fair Value Assumptions, Expected Term Expected volatility Fair Value Assumptions, Expected Volatility Rate Dividend yield Fair Value Assumptions, Expected Dividend Rate Number of Warrants Number of Warrants [Abstract] NA. Warrants outstanding at beginning of year Class of Warrant or Right, Outstanding Additions Warrant Issued Number Number of warrants issued during the period pursuant to public offering. Warrants outstanding at end of period Changes in the estimated fair value for warrant liability Financial Liabilities Fair Value Disclosure [Abstract] Fair value at beginning of year Warrants Not Settleable in Cash, Fair Value Disclosure Additions, pursuant to public offering Warrants Issued Value Amount of warrants issued during the period pursuant to public offering. Fair value at end of year Fair Value, by Balance Sheet Grouping [Table] Fair Value, by Balance Sheet Grouping [Table] Long-term Debt, Type [Axis] Long-term Debt, Type [Axis] Long-term Debt, Type [Domain] Long-term Debt, Type [Domain] Senior Notes Senior Notes [Member] Measurement Basis [Axis] Measurement Basis [Axis] Fair Value Measurement [Domain] Fair Value Measurement [Domain] Portion at Fair Value Measurement [Member] Portion at Fair Value Measurement [Member] Carrying Amount Reported Value Measurement [Member] Estimated Fair Value Estimate of Fair Value Measurement [Member] Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items] Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items] Convertible senior notes, net Convertible Debt Convertible debt, fair value Convertible Debt, Fair Value Disclosures Fair value, liability related to sale of future royalties Common stock, value, issued Common Stock, Value, Issued Royalty purchase agreement arrangements consideration Royalty Purchase Agreement Arrangements Consideration Royalty Purchase Agreement Arrangements Consideration Financial Information Based on Geographic Location of Facilities Schedule of Segment Reporting Information, by Segment [Table Text Block] Options, outstanding [Roll Forward] Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward] Options outstanding, start of year (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number Exercise of stock options (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period Expired or forfeited (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period Options outstanding, end of year (in shares) Vested as of June 30, 2018 (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Number of Shares Weighted Average Exercise Price [Roll Forward] Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested, Number of Shares [Roll Forward] Weighted average exercise price, options outstanding, start of year (in USD per share) Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price Granted (in USD per share) Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price Exercised (in USD per share) Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price Expired or forfeited (in USD per share) Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price Weighted average exercise price, options outstanding, end of year (in USD per share) Vested as of June 30, 2018 (in USD per share) Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price Weighted average remaining contractual term (years) [Roll Forward] Weighted average remaining contractual term (years) [Roll Forward] Weighted average remaining contractual term (years) [Roll Forward] Weighted average remaining contractual term Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term Weighted average remaining contractual term, vested as of June 30, 2018 Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term Intrinsic value [Roll Forward] Intrinsic value [Roll Forward] Intrinsic value [Roll Forward] Options, outstanding, intrinsic value, start of year Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value Options, outstanding, intrinsic value, end of year Options, vested, outstanding, intrinsic value as of 30 June 2018 Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value Related Party Transactions Related Party Transactions Disclosure [Text Block] Property, Plant and Equipment [Abstract] Depreciation and amortization expense Quarterly Results of Operations Quarterly Financial Information [Text Block] Class of Warrant or Right [Table] Class of Warrant or Right [Table] Scenario [Axis] Scenario [Axis] Scenario, Unspecified [Domain] Scenario, Unspecified [Domain] Scenario, Previously Reported Scenario, Previously Reported [Member] IPO IPO [Member] Type of Arrangement and Non-arrangement Transactions [Axis] Type of Arrangement and Non-arrangement Transactions [Axis] Arrangements and Non-arrangement Transactions [Domain] Arrangements and Non-arrangement Transactions [Domain] Funding And Purchase Agreements Funding And Purchase Agreements [Member] This member stands for funding and purchase agreements. Securities Purchase Agreement Securities Purchase Agreement [Member] Represents information pertaining to purchase agreement. Seattle Genetics, Inc., (“SGEN”) Seattle Genetics Inc [Member] Represents the information pertaining to Seattle Genetics, Inc. Common and preferred shares authorized (in shares) Common And Preferred Shares Authorized Common and preferred shares authorized. Issuance of convertible preferred stock (in USD per share) Issuance of Convertible Preferred Stock, Per Share Issuance of Convertible Preferred Stock, Per Share Proceeds from issuance of convertible preferred stock Proceeds from Issuance of Convertible Preferred Stock Convertible preferred stock, shares issued upon conversion (in shares) Convertible Preferred Stock, Shares Issued upon Conversion Share price (in USD per share) Share Price Conversion of shares (in shares) Conversion of Stock, Shares Issued Shares, issued (in shares) Shares, Issued Collaborative arrangement purchase price Collaborative Arrangement Purchase Price The amount of collaborative agreement purchase price. Agreement purchase shares of common stock (in shares) Stock Issued During Period, Shares, New Issues Gross proceeds from sale of common stock Gross Proceeds From Issuance Of Common Stock Represents gross proceeds from issuance of common stock before deducting underwriting discounts and commissions and estimated expense. Warrants term Debt Instrument, Term Shares that warrants can purchase (in shares) Class of Warrant or Right, Number of Securities Called by Warrants or Rights Fair value of warrants Class of Warrant or Right, Fair Value Fair value of warrants during the reporting period. Exercise of warrants (in shares) Exercise of Warrants Number of warrants exercised. Net proceeds from sale of common stock Aggregate purchase price of common stock Aggregate Purchase Price of Common Stock The amount of aggregate purchase price of common stock. Increase in fair value of warrants exercised Increase in Fair Value Of Warrants Exercised Increase in Fair Value Of Warrants Exercised Exercise price of warrant (in USD per share) Class of Warrant or Right, Exercise Price of Warrants or Rights Warrants exercised (in shares) Warrants outstanding (in shares) Inventory Disclosure [Abstract] Inventory Inventory Disclosure [Text Block] Estimated Fair Value of Financial Instruments Fair Value Disclosures [Text Block] Retirement Benefits [Abstract] Defined Contribution Plans Pension and Other Postretirement Benefits Disclosure [Text Block] NOL carry forwards Deferred Tax Assets, Operating Loss Carryforwards Research and development credits Deferred Tax Assets, Tax Credit Carryforwards, Research Property and equipment Deferred Tax Assets, Property, Plant and Equipment Liability related to sale of future royalties Deferred Tax Assets, Deferred Income Other Deferred Tax Assets, Other Total Deferred Tax Assets, Gross Valuation allowance Deferred Tax Assets, Valuation Allowance Net deferred assets Deferred Tax Assets, Net Property and equipment, DTL Deferred Tax Liabilities, Property, Plant and Equipment Net deferred assets and liabilities Deferred Income Tax Assets and Liabilities Deferred Income Tax Assets and Liabilities Schedule of Long-term Debt Instruments [Table] Schedule of Long-term Debt Instruments [Table] Debt Instrument [Axis] Debt Instrument [Axis] Debt Instrument, Name [Domain] Debt Instrument, Name [Domain] Four Point Seven Five Percent Convertible Senior Notes [Member] Four Point Seven Five Percent Convertible Senior Notes [Member] Four point seven five percent convertible senior notes. Debt Instrument [Line Items] Debt Instrument [Line Items] Debt instrument, face amount Debt Instrument, Face Amount Proceeds from debt, net of issuance costs Proceeds from Debt, Net of Issuance Costs Debt instrument, maturity date Debt Instrument, Maturity Date Payments of debt issuance costs Payments of Debt Issuance Costs Debt instrument, interest rate, stated percentage Debt Instrument, Interest Rate, Stated Percentage Debt instrument, interest rate, effective percentage Debt Instrument, Interest Rate, Effective Percentage Conversion ratio Debt Instrument, Convertible, Conversion Ratio Conversion price Debt Instrument, Convertible, Conversion Price Percentage of principal amount redeemed Debt Instrument, Redemption Price, Percentage of Principal Amount Redeemed Denominator of principal amount of debt Used In Conversion Denominator Of Principal Amount Of Debt Used In Conversion Represents the denomination of the principal amount of debt that is used in conversion calculations. Issuance of common stock due to debt conversion Debt Conversion, Converted Instrument, Shares Issued Convertible beneficial conversion feature (in shares) Debt Instrument Convertible Beneficial Conversion Feature, Aggregate Number of Shares The amount of shares by which the convertible debt's if-converted value exceeds its principle amount of shares at the balance sheet date, regardless of whether the instrument is currently convertible. This element applies to public companies only. Induced conversion of convertible debt expense Induced Conversion of Convertible Debt Expense Senior notes Senior Notes Accelerated amortization of financing costs Accelerated Amortization Of Financing Costs Amount of accelerated amortization of financing costs attributable to debt issuance costs. Collaboration Agreement License and Collaboration Agreements [Abstract] Guarantor Obligations, Nature [Axis] Guarantor Obligations, Nature [Axis] Guarantor Obligations, Nature [Domain] Guarantor Obligations, Nature [Domain] The Bayer Group (formerly Algeta ASA) Bayer Group [Member] Bayer group. Upfront cash payment and other payments received under collaboration agreement Upfront Cash Payment And Other Payments Received Under Collaboration Agreement Upfront cash payment and other payments received under collaboration agreement. Financial Instruments Recorded on Condensed Consolidated Balance Sheets Fair Value, Assets Measured on Recurring and Nonrecurring Basis [Table Text Block] Schedule of Carrying Amounts and Estimated Fair Values (Level 2) of Debt Instruments Schedule of Carrying Values and Estimated Fair Values of Debt Instruments [Table Text Block] Schedule of assumptions used in estimating fair value of the warrant liability Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques [Table Text Block] Schedule of warrant liability Schedule of Fair Value Measurements, Warrant Liability [Table Text Block] Tabular disclosure of warrant liability measured at fair value. Nonvested, compensation not yet recognized, stock options Employee Service Share-based Compensation, Nonvested Awards, Compensation Not yet Recognized, Stock Options Nonvested, compensation not yet recognized, period Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition Options, non-vested, weighted average grant date fair value (in USD per share) Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested, Weighted Average Grant Date Fair Value Options, vested in period, fair value Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value Options, exercises in period, intrinsic value Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value Accumulated Other Comprehensive (Loss) Income Comprehensive Income (Loss) Note [Text Block] Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table Text Block] Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block] Share-based Compensation, Stock Options, Activity Share-based Compensation, Stock Options, Activity [Table Text Block] Schedule of Share-based Compensation, Restricted Stock and Restricted Stock Units Activity Schedule of Share-based Compensation, Restricted Stock and Restricted Stock Units Activity [Table Text Block] Schedule of Share-based Compensation, Performance Stock and Performance Stock Units Activity Schedule of Share-based Compensation, Performance Stock and Performance Stock Units Activity [Table Text Block] Schedule of Share-based Compensation, Performance Stock and Performance Stock Units Activity [Table Text Block] Debt Deferred Revenue Disclosure [Text Block] Operating Leases, Future Minimum Payments Due, Fiscal Year Maturity [Abstract] 2019 Operating Leases, Future Minimum Payments Due, Next Twelve Months 2020 Operating Leases, Future Minimum Payments, Due in Two Years 2021 Operating Leases, Future Minimum Payments, Due in Three Years 2022 Operating Leases, Future Minimum Payments, Due in Four Years 2023 Operating Leases, Future Minimum Payments, Due in Five Years Thereafter Operating Leases, Future Minimum Payments, Due Thereafter Property and Equipment Property, Plant and Equipment Disclosure [Text Block] Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward] Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward] Non-vested, start of year (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number Granted (in shares) Vested/Exercised (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period Non-vested, end of year (in shares) Weighted average grant date fair value [Roll Forward] Weighted average grant date fair value [Roll Forward] Weighted average grant date fair value [Roll Forward] Nonvested, weighted average grant date fair value, start of year (in USD per share) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value Grants in period, weighted average grant date fair value (in USD per share) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value Vested/exercised, weighted average grant date fair value (in USD per share) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value Nonvested, weighted average grant date fair value, end of year (in USD per share) Threshold consecutive trading days Share-based Compensation Arrangement by Share-based Payment Award, Threshold Consecutive Trading Days Share-based Compensation Arrangement by Share-based Payment Award, Threshold Consecutive Trading Days Award requisite service period Share-based Compensation Arrangement by Share-based Payment Award, Award Requisite Service Period Nonvested, compensation not yet recognized, PSU Employee Service Share-based Compensation, Nonvested Awards, Compensation Not yet Recognized, Share-based Awards Other than Options Operating Loss Carryforwards [Table] Operating Loss Carryforwards [Table] Gain Contingencies, Nature [Axis] Gain Contingencies, Nature [Axis] Gain Contingency, Nature [Domain] Gain Contingency, Nature [Domain] Reduction in Taxes [Member] Reduction in Taxes [Member] Operating Loss Carryforwards [Line Items] Operating Loss Carryforwards [Line Items] Operating loss carry forwards for federal income tax Deferred Tax Assets, Operating Loss Carryforwards, Domestic Operating loss carry forwards for state income tax Deferred Tax Assets, Operating Loss Carryforwards, State and Local Net operating loss carry forwards expiration year Operating Loss Carry Forward Expiration Year Operating Loss Carry Forward Expiration Year Income tax expense (benefit) Operating loss carryforward resulting from sale Operating Loss Carryforward Resulting From Sale Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws that resulted from a sale of taxing authority certificate(s). Deferred tax assets tax credit carryforwards research and development Deferred Tax Assets Tax Credit Carryforwards Research And Development. Amount before allocation of valuation allowances of deferred tax asset attributable to deductible research tax credit carryforwards resulting from a sale of taxing authority certificate(s). Statutory rate Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent Statement of Stockholders' Equity [Abstract] Equity Components [Axis] Equity Components [Axis] Equity Component [Domain] Equity Component [Domain] Common Stock Common Stock [Member] Capital Contributed in Excess of Par Additional Paid-in Capital [Member] Treasury Stock Treasury Stock [Member] Accumulated Deficit Retained Earnings [Member] Accumulated Other Comprehensive Income (Loss) AOCI Attributable to Parent [Member] Noncontrolling Interest Noncontrolling Interest [Member] Beginning balance (in shares) Beginning balance Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest Reclassification of warrant liability to equity Reclassification of Warrant Liability to Equity Reclassification of Warrant Liability to Equity Exercise of common stock warrants (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Warrants, Exercises in Period Share-based Compensation Arrangement by Share-based Payment Award, Warrants, Exercises in Period Exercise of common stock warrants Stock Issued During Period, Value, Warrants Exercised Stock Issued During Period, Value, Warrants Exercised Exercise of stock options (in shares) Exercise of stock options, net Stock Issued During Period, Value, Stock Options Exercised Stock based compensation (in shares) Stock based compensation Stock Issued During Period, Value, Share-based Compensation, Net of Forfeitures Conversion of RSU's for tax withholding payments (in shares) Shares Paid for Tax Withholding for Share Based Compensation Conversion of RSU's for tax withholding payments Adjustments Related to Tax Withholding for Share-based Compensation Other comprehensive income Issuance of preferred stock (in shares) Preferred Stock Issued During Period Shares New Issues Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt Issuance of preferred stock, net Preferred Stock Issued During Period Value New Issues Value of all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by shareholders, which is net of related treasury stock. May be all or a portion of the number of preferred shares authorized. These shares represent the ownership interest of the preferred shareholders. Issuance of common stock (in shares) Issuance of common stock, net Stock Issued During Period, Value, New Issues Proceeds of public offering allocated to warrant liability Adjustments to Additional Paid in Capital, Proceeds From Offering Warrants Adjustments to Additional Paid in Capital, Proceeds From Offering Warrants Conversion of preferred shares (in shares) Stock Issued During Period, Shares, Conversion of Units Conversion of Preferred Shares Stock Issued During Period, Value, Conversion of Convertible Securities, Net of Adjustments Issuance of common stock due to debt conversion (in shares) Issuance of common stock due to debt conversion Debt Conversion, Converted Instrument, Amount Ending balance Ending balance (in shares) Restricted Stock Units (RSUs) Restricted Stock Units (RSUs) [Member] Restricted units, outstanding [Roll Forward] Nonvested, compensation not yet recognized, RSU Subsidiary or Equity Method Investee, Sale of Stock by Subsidiary or Equity Investee [Table] Subsidiary or Equity Method Investee, Sale of Stock by Subsidiary or Equity Investee [Table] Over-Allotment Option Over-Allotment Option [Member] Common Stock Purchase Agreement Common Stock Purchase Agreement [Member] This member stands for common stock purchase agreement. Subsidiary, Sale of Stock [Line Items] Subsidiary, Sale of Stock [Line Items] Number of subsidiaries Number Of Subsidiaries Number Of Subsidiaries Cash, cash equivalents and marketable securities Cash, Cash Equivalents, and Short-term Investments Shares, issued (in shares) Sale of Stock, Number of Shares Issued in Transaction Share price (in USD per share) Sale of Stock, Price Per Share Proceeds from public offering Underwriting expense Payments of Stock Issuance Costs Percentage of premium over share price Percentage of Premium Over Share Price Represent premium over the stocks. Increase in cash due to collaborative agreements Increase in Cash Due to Collaborative Agreements The amount of increase in cash due to collaborative agreements. Property, Plant and Equipment [Table] Property, Plant and Equipment [Table] Property, Plant and Equipment, Type [Axis] Property, Plant and Equipment, Type [Axis] Property, Plant and Equipment, Type [Domain] Property, Plant and Equipment, Type [Domain] Machinery and equipment Machinery and Equipment [Member] Leasehold improvements Leasehold Improvements [Member] Furniture and fixtures Furniture and Fixtures [Member] Computer equipment Computer Equipment [Member] Property, Plant and Equipment [Line Items] Property, Plant and Equipment [Line Items] Property and equipment, gross Property, Plant and Equipment, Gross Accumulated depreciation and amortization Property, plant and equipment, net Property, Plant and Equipment, Useful Life Property, Plant and Equipment, Useful Life Inventory Inventory, Net Summary of Property and Equipment Property, Plant and Equipment [Table Text Block] Statutory rate Foreign income tax Effective Income Tax Rate Reconciliation, Foreign Income Tax Rate Differential, Percent Change in valuation allowance Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent State income taxes, (net of federal tax benefit) Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent Permanent differences, (primarily warrant-related expenses) Effective Income Tax Rate Reconciliation, Nondeductible Expense, Percent Other Effective Income Tax Rate Reconciliation, Tax Credit, Other, Percent Effective rate Effective Income Tax Rate Reconciliation, Percent Stockholders' Equity Note [Abstract] Stockholders’ Equity (Deficit) Stockholders' Equity Note Disclosure [Text Block] Schedule of Minimum Lease Commitments for Facilities Schedule of Future Minimum Rental Payments for Operating Leases [Table Text Block] Common stock equivalents excluded from the diluted per share calculation Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount Share-Based Compensation Disclosure of Compensation Related Costs, Share-based Payments [Text Block] Accumulated Other Comprehensive (Loss) Income [Table] Accumulated Other Comprehensive Income (Loss) [Table] Currency Translation Adjustments [Member] Accumulated Foreign Currency Adjustment Attributable to Parent [Member] Net Unrealized Gains (Losses) on Available-for-Sale Securities [Member] Accumulated Net Investment Gain (Loss) Attributable to Parent [Member] Accumulated Other Comprehensive (Loss) Income [Line Items] Accumulated Other Comprehensive Income (Loss) [Line Items] AOCI Attributable to Parent [Roll Forward] AOCI Attributable to Parent, Net of Tax [Roll Forward] Other comprehensive (loss) income before reclassifications Other Comprehensive Income (Loss), before Reclassifications, Net of Tax Amounts reclassified from accumulated other comprehensive income (loss) Reclassification from Accumulated Other Comprehensive Income, Current Period, Net of Tax Net other comprehensive loss for the year Net Other Comprehensive Income (Loss) Net Other Comprehensive Income (Loss) Aggregate company contributions to its benefit plans Defined Benefit Plan, Plan Assets, Contributions by Employer Collaborative arrangement purchase price Payments For Future Royalties Payments For Future Royalties Collaborative Arrangement Royalty Rate as Percentage of Net Sales Royalty Purchase Arrangement, Royalty Rate as Percentage of Net Sales The percentage of collaborative arrangement royalty rate on net sales. Collaborative Arrangement Maximum Royalty Amount Royalty Purchase Arrangement, Annual Sales Limit, Maximum The amount of collaborative arrangement royalty. Collaborative Arrangement Royalty Rate as Percentage of Excess of Global Annual Sales Threshold Limit Royalty Purchase Arrangement, Royalty Rate as Percentage of Excess of Global Annual Sales Threshold Limit The percentage of collaborative arrangement royalty rate on excess of global annual sales threshold limit. Collaborative Arrangement Excess of Global Annual Sales Threshold Limit Royalty Purchase Arrangement, Excess Global Annual Sales Limit, Minimum Sale of stock, consideration received on transaction Sale of Stock, Consideration Received on Transaction Annual interest rate in calculating liability related to sale of future royalties Annual Interest Rate In Calculating Liability Related To Sale Of Future Royalties Annual Interest Rate In Calculating Liability Related To Sale Of Future Royalties ASSETS Assets [Abstract] Assets, Current [Abstract] Assets, Current [Abstract] Cash and cash equivalents Marketable securities Available-for-sale Securities, Debt Securities, Current Accounts receivable, net of allowances of $0 and $9,371 at June 30, 2018, and 2017, respectively Accounts Receivable, Net, Current Prepaid expenses Prepaid Expense, Current Other current assets Other Assets, Current Total current assets Assets, Current Property and equipment, net of accumulated depreciation of $30,858,228 and $29,560,955 at June 30, 2018 and 2017, respectively Other long-term assets Other Assets, Noncurrent Total Assets LIABILITIES AND STOCKHOLDERS' EQUITY (DEFICIT) Liabilities and Equity [Abstract] Liabilities, Current [Abstract] Liabilities, Current [Abstract] Accounts payable and accrued expenses Liability related to sale of future royalties - current Liabilities Related To The Sale Of Future Royalties, Current Liabilities Related To The Sale Of Future Royalties, Current Warrant liabilities Warrants and Rights Outstanding Deferred revenues Deferred Revenue, Current Total current liabilities Liabilities, Current Convertible Debt, Noncurrent Convertible Debt, Noncurrent Liability related to sale of future royalties - non-current Liabilities Related To The Sale Of Future Royalties, Noncurrent Liabilities Related To The Sale Of Future Royalties, Noncurrent Other long-term liabilities Other Liabilities, Noncurrent Total Liabilities Liabilities Commitments and Contingencies (Note 15) Commitments and Contingencies Stockholders’ Equity (Deficit): Stockholders' Equity Attributable to Parent [Abstract] Convertible preferred stock, $0.1 par value; authorized 10,000,000 shares; no shares issued and outstanding at June 30, 2018 and 1,000,000 shares issued and outstanding at June 30, 2017 Convertible Preferred Stock, Nonredeemable or Redeemable, Issuer Option, Value Common stock, $0.1 par value; authorized 250,000,000 shares issued 186,801,159 shares and outstanding 186,766,434 shares at June 30, 2018; shares issued 110,344,643 shares and outstanding 110,309,918 shares at June 30, 2017 Capital contributed in excess of par Additional Paid in Capital, Common Stock Treasury stock, at cost: 34,725 shares at June 30, 2018 and 2017 Treasury Stock, Value Accumulated deficit Retained Earnings (Accumulated Deficit) Accumulated other comprehensive loss Accumulated Other Comprehensive Income (Loss), Net of Tax Total Immunomedics, Inc. stockholders' equity (deficit) Stockholders' Equity Attributable to Parent Noncontrolling interest in subsidiary Stockholders' Equity Attributable to Noncontrolling Interest Total stockholder's equity (deficit) Total Liabilities and Stockholders' Equity Liabilities and Equity Collaboration Agreement License And Collaboration Agreements [Text Block] License And Collaboration Agreements [Text Block] Commitments and Contingencies Commitments and Contingencies Disclosure [Text Block] Consolidated Statements of Comprehensive Loss Data: Consolidated Statement Of Operations [Abstract] Consolidated Statement Of Operations [Abstract] Net loss attributable to Immunomedics, Inc. stockholders Expense for Income Taxes Schedule of Components of Income Tax Expense (Benefit) [Table Text Block] Reconciliation of Statutory Tax Rates and Effective Tax Rates Schedule of Effective Income Tax Rate Reconciliation [Table Text Block] Tax Effects of Temporary Differences in Deferred Tax Assets Schedule of Deferred Tax Assets and Liabilities [Table Text Block]